Genomic Health announces results from studies involving sequencing from paraffin Genomic Health announced the results of two studies demonstrating that DNA strand-of-origin information can help further refine the identification of prognostic biomarkers, and that tumor specific gene mutations can be effectively examined using archival fixed paraffin embedded tumor tissue, enabling an improved and more practical process of tumor analysis.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Genomic Health's Oncotype DX for prostate cancer shows positive results Genomic Health announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research demonstrating that the Oncotype DX Genomic Prostate Score predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a predictor of biochemical recurrence, a rise in prostate-specific antigen following surgery, which is a measure of longer-term outcomes for aggressive disease. Additional endpoints of this prostate cancer study include the development of metastatic disease and outcomes in African-American patients.